Business
Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead
OSAKA, Japan, January 29, 2026--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incremental Growth & Launch Products revenue and VYVANSE erosion is narrowing, and operational efficiencies drove year-on-year reductions in operating expenses, including R&D. The company raised its full-year forecasts based on cost discipline and FX tailwind, while its Revenue Management Guidance has been u
About this update from Takeda Pharmaceutical Co. Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":320,"url":"https://media.zenfs.com/en/business-wire.com/95d00909ba743813950812d28a90253e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oK9QVWKzw.Bapbt3M18PVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/95d00909ba743813950812d28a90253e","width":480,"height":320}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Year-to-Date Revenue Declined by 2.8% at Constant Exchange Rate (CER), 3.3% at Actual Exchange Rates (AER); Impact of VYVANSE® Generics is Tapering Off","length":151,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Core Operating Profit Declined by 3.4% at both CER and AER Year to Date","length":71,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Reported Operating Profit Increased by 1.2% at AER Year to Date, Lower Restructuring Expenses More Than Offset Impairment","length":121,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":343,"olType":false},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"text","content":"OSAKA, Japan, January 29, 2026--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2025 (nine months ended December 31, 2025). The gap between incremental Growth & Launch Products revenue and VYVANSE erosion is narrowing, and operational efficiencies drove year-on-year reductions in operating expenses, including R&D. The company raised its full-year forecasts based on cost discipline and FX tailwind, while its Revenue Management Guidance has been updated primarily due to the impact of VYVANSE generics.","length":580,"tagName":"p"},{"type":"text","content":"Takeda is positioned for long-term growth and has multiple late-stage programs with multibillion-dollar peak revenue potential. Following the positive readouts from Phase 3 studies in 2025, the company has submitted New Drug Applications (NDAs) for oveporexton and rusfertide and is on track to file an NDA for zasocitinib. Each of these programs, which Takeda expects to launch within the next 18 months, has the potential to redefine standards of care, transform patient lives and contribute to Tak...